Authors
Latest:
Dr Taylor on the Integration of Tagraxofusp Into the Frontline Treatment Armamentarium for BPDCNJustin W. Taylor, MD, discusses the evolution of frontline treatment options for patients with blastic plasmacytoid dendritic cell neoplasm, including the integration of tagraxofusp-erzs into the treatment armamentarium in this disease space.
Latest:
Dr. Patel on CheckMate-227 Results in Advanced NSCLCJyoti D. Patel, MD, discusses the results of the CheckMate-227 trial, which looked at an immunotherapy combination versus chemotherapy in patients with advanced non–small cell lung cancer.
Latest:
Dr. Malhotra on Challenges with Precision Medicine in Advanced Solid TumorsJyoti Malhotra, MD, MPH, discusses challenges with precision medicine in advanced solid tumors.
Latest:
Dr Patel on Findings From the TRUST-II Trial in ROS1+ NSCLCJyoti Patel, MD, discusses the implications of the TRUST-II trial in locally advanced or metastatic ROS1-positive NSCLC, regardless of prior TKI exposure.
Latest:
Helping Cancer Patients Quit Smoking Should Be a Standard of CareMost oncologists do not regularly provide evidence-based tobacco cessation support for patients with cancer who smoke. However, addressing tobacco use is not as difficult as some might think.
Latest:
Dr. Mody on Progress Made With Y-90 in Hepatocellular CarcinomaKabir Mody, MD discusses new directions with yttrium-90 glass microspheres in hepatocellular carcinoma as demonstrated in the retrospective LEGACY study.
Latest:
Unmet Needs and Future Direction in HER2+ Breast CancerThe panel looks to the future landscape for HER2+ breast cancer, highlighting emerging treatment practices and currently unmet needs.
Latest:
CLL in the Era of Targeted TherapiesOver the past few years, remarkable advances have been achieved in the field of chronic lymphocytic leukemia by rationally targeting pathways overexpressed and used by the malignant clone for proliferation and survival.
Latest:
Dr Raghav on the Rationale Behind DESTINY-CRC02 in HER2+ mCRCKanwal P. S. Raghav, MBBS, MD, discusses the rationale behind the phase 2 DESTINY-CRC02 trial evaluating fam-trastuzumab deruxtecan-nxki in patients with metastatic colorectal cancer (mCRC) with HER2 amplification or overexpression.
Latest:
Metastatic Colorectal Cancer: Future Directions in CareExpert panelists identify key takeaways and share their excitement for future directions in the management of metastatic colorectal cancer.
Latest:
Dr. Bhalla on Sensitizing TNBC to PARP Inhibitors and CisplatinKapil N. Bhalla, MD, from the University of Kansas Cancer Center, describes an in vivo study that examined treatment with histone deacetylase inhibitors in triple-negative breast cancer cells.
Latest:
Immunotherapy Combined With Chemotherapy for Pancreatic Cancer: A Game Changer?This article reviews up-to-date clinical studies combining chemotherapy with immunotherapy; it also explains the rationale for this combination in treatment of pancreatic cancer.
Latest:
Kareem Abdul-Jabbar Discusses Living With CMLKareem Abdul-Jabbar, retired NBA player for the Milwaukee Bucks and the Los Angeles Lakers, discusses his experience with chronic myeloid leukemia‎ (CML) at the 20th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas and Myeloma, held March 18.
Latest:
Dr. Hoffman on the Urologist's Influence on Treatment ChoiceKaren E. Hoffman, MD, MHSc, MPH, from the MD Anderson Cancer Center, describes the diagnosing urologist's influence on the initial treatment selected for elderly men with favorable prostate cancer.
Latest:
The Rationale for Investigating DNA-PK as a Target in Prostate CancerKaren E. Knudsen, PhD, discusses the rationale for investigating DNA-dependent protein kinase as a target in prostate cancer.
Latest:
Dr. Lu on the Challenges of Risk-Reducing Salpingo-Oophorectomy in Ovarian CancerKaren H. Lu, MD, professor and chair in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center discusses the challenges of risk-reducing salpingo-oophorectomy in women with an increased risk for hereditary ovarian cancer.
Latest:
Beyond PSA: A Summary Review of Predictive/Prognostic Biomarkers in Prostate CancerAlthough prostate cancer (PC) is the most common solid tumor malignancy among men in the Western Hemisphere, disease-specific mortality remains low, primarily due to optimized screening, diagnosis, and treatment.
Latest:
Karen Hagemaster on Chemo Documentation StudyKaren Hagemaster from Advocate Good Samaritan Hospital on Chemotherapy Documentation Study
Latest:
Developing Best Practices to Mitigate Opioid Abuse Is a Priority in Cancer CareOpioids are prescribed to manage cancer pain because the benefits generally outweigh the risks and because of the ethical imperative for quick relief. However, patients are exposed to a degree of risk for misuse and abuse.
Latest:
Innovative Use of Technology for Palliative CareInnovative models for palliative care delivery and primary palliative care training are springing up to address the demand–capacity mismatch.
Latest:
Most Patients in Need of HCT Can Now Get TransplantsDue to great progress in alternative donor transplants, almost all transplant-eligible patients, up to age 75 years, in 2017 will be able to find a suitable donor and proceed to transplant, a major advance over the past 10 years.
Latest:
The Importance of the Oncologist in Physician DispensingKaren Kellogg, PharmD, Cardinal Health, discusses the important role that the oncologist plays in dispensing.
